Dec 30, 2025 • ts2.tech
SOMEWHAT-BEARISH
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade
Catalyst Pharmaceuticals shares dropped 3% in afternoon trading, continuing a two-day slide, while biotech ETFs also underperformed the broader market in thin year-end trading. Investors are looking ahead to the Federal Reserve's meeting minutes and Catalyst's next public appearance in January. Analyst sentiment remains largely positive, with an average 12-month price target implying significant upside.
Dec 24, 2025 • MarketBeat
BULLISH
Voya Investment Management LLC Has $8.79 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX
Voya Investment Management LLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 25.1% in the third quarter, now owning 446,399 shares valued at approximately $8.79 million. The biopharmaceutical company's board has also approved a $200 million share repurchase program, signaling management's belief that the stock is undervalued. Catalyst Pharmaceuticals has a consensus analyst "Buy" rating and a target price of around $32.67.
Dec 24, 2025 • MarketBeat
BULLISH
Texas Permanent School Fund Corp Boosts Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX
Texas Permanent School Fund Corp significantly increased its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 178.8% in Q2, bringing its total to 67,934 shares valued at $1.47 million. This move is part of a broader trend of institutional investors, including Goldman Sachs and Bank of America, increasing their positions in the biopharmaceutical company, which has seen its institutional ownership reach 79.22%. Catalyst Pharmaceuticals has also authorized a $200 million share buyback program, and Wall Street analysts currently rate the stock as a "Buy" with an average price target of $32.67.
Dec 23, 2025 • MarketBeat
SOMEWHAT-BULLISH
Wedge Capital Management L L P NC Makes New $2.86 Million Investment in Catalyst Pharmaceuticals, Inc. $CPRX
Wedge Capital Management L L P NC has initiated a new position in Catalyst Pharmaceuticals (NASDAQ:CPRX) during the third quarter, acquiring 145,168 shares valued at approximately $2.86 million. This investment comes amid positive analyst sentiment, with an average "Buy" rating and a target price of $32.67 for the biopharmaceutical company. Catalyst Pharmaceuticals has also authorized a $200 million share repurchase program, indicating the board believes its shares are undervalued.
Dec 23, 2025 • 富途牛牛
NEUTRAL
Catalyst Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains
Catalyst Pharmaceuticals Inc. stock underperformed its competitors on Wednesday, despite daily gains. The article briefly mentions Unity Software's fourth-quarter financial results, including a revenue increase of 35% year-over-year to $609 million and a quarterly loss of 66 cents per share. However, the full article content is restricted due to copyright issues.
Dec 23, 2025 • MarketBeat
SOMEWHAT-BULLISH
Toth Financial Advisory Corp Has $42,000 Stake in Catalyst Pharmaceuticals, Inc. $CPRX
Toth Financial Advisory Corp significantly reduced its stake in Catalyst Pharmaceuticals (NASDAQ: CPRX) by 96.5% in Q3, now holding 2,150 shares valued at $42,000. Despite this, institutional ownership remains high at 79.22%, and analysts maintain an average "Buy" rating with an average target price of $32.67. Additionally, the company has approved a $200 million share repurchase program, indicating board confidence in the stock's value.